Tuesday, July 31, 2012 11:41:41 AM
You just hit the nail on the head.
The appraisal was for 2008. Is CGAQ telling us that they signed
a SALES agreement as oppose to a PURCHASE agreement and
that they are relying on a 2008 appraisal ?
Are they telling us they cant afford a new appraisal ?That is
a huge sum of money to pay without having an appraisal done.
Who came up with the new value of the property of $13,000.00 U.S..
The condominiums were sold to different individuals when first
built . Has this ownership changed since?
I also notice it states that it (CGAQ) has signed a sales agreement.
Has the other side also signed and agreed to the purchase price ?
You would also think that Mr. Leiber from what I have read in the
posts would already have a lender on hand. " Swank is in the middle
of negotiations with several lenders".
WE ( SOME OF US ) DEMAND ANOTHER PRESS RELEASE THAT CLARIFIES
THE AGREEMENT, THAT THIS WON'T TURN OUT TO BE LIKE THE
HIPODROMO V CENTENARIO RACETRACK DEAL.
The appraisal was for 2008. Is CGAQ telling us that they signed
a SALES agreement as oppose to a PURCHASE agreement and
that they are relying on a 2008 appraisal ?
Are they telling us they cant afford a new appraisal ?That is
a huge sum of money to pay without having an appraisal done.
Who came up with the new value of the property of $13,000.00 U.S..
The condominiums were sold to different individuals when first
built . Has this ownership changed since?
I also notice it states that it (CGAQ) has signed a sales agreement.
Has the other side also signed and agreed to the purchase price ?
You would also think that Mr. Leiber from what I have read in the
posts would already have a lender on hand. " Swank is in the middle
of negotiations with several lenders".
WE ( SOME OF US ) DEMAND ANOTHER PRESS RELEASE THAT CLARIFIES
THE AGREEMENT, THAT THIS WON'T TURN OUT TO BE LIKE THE
HIPODROMO V CENTENARIO RACETRACK DEAL.
Recent BSEM News
- BioStem Technologies Announces $2.5 Million Private Placement Financing with its First Institutional Investor • GlobeNewswire Inc. • 05/22/2026 11:00:00 AM
- BioStem Technologies Announces Notice of Allowance for Four U.S. Design Patent Applications Covering Fenestrated Human Placental Allografts and One European Patent • GlobeNewswire Inc. • 05/20/2026 01:00:00 PM
- BioStem Technologies Reports First Quarter 2026 Financial Results • GlobeNewswire Inc. • 05/14/2026 08:05:00 PM
- BioStem Technologies to Host First Quarter 2026 Financial Results Conference Call on May 14, 2026 • GlobeNewswire Inc. • 04/30/2026 08:05:00 PM
- BioStem Strengthens Leadership Team with Appointment of Katherine Gorrell as Chief Legal & Compliance Officer • GlobeNewswire Inc. • 04/30/2026 11:00:00 AM
- BioStem Technologies to Showcase Innovation and Clinical Evidence at Symposium on Advanced Wound Care Spring 2026 • GlobeNewswire Inc. • 04/08/2026 11:00:00 AM
- BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/31/2026 08:05:00 PM
- BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025 • GlobeNewswire Inc. • 03/30/2026 11:00:00 AM
- BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/24/2026 08:05:00 PM
- BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair • GlobeNewswire Inc. • 03/23/2026 03:40:56 PM
- BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair • GlobeNewswire Inc. • 03/23/2026 11:00:00 AM
- BioStem Technologies to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 24, 2026 • GlobeNewswire Inc. • 03/11/2026 08:05:00 PM
- BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference • GlobeNewswire Inc. • 02/20/2026 12:00:00 PM
- BioStem Technologies Highlights Alignment with FDA’s Openness to Bayesian Statistical Approaches in Clinical Research • GlobeNewswire Inc. • 02/03/2026 09:05:00 PM
- BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings’ Surgical and Wound Care Business • GlobeNewswire Inc. • 01/21/2026 10:30:00 PM
- BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes • GlobeNewswire Inc. • 01/07/2026 09:05:00 PM
- BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes • GlobeNewswire Inc. • 12/18/2025 12:00:00 PM
- BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference • GlobeNewswire Inc. • 12/10/2025 12:00:00 PM
- BioStem Technologies Expands Product Access in Medicaid • GlobeNewswire Inc. • 11/25/2025 01:59:13 PM
- BioStem Technologies Reports Third Quarter 2025 Financial Results • GlobeNewswire Inc. • 11/13/2025 09:02:00 PM
- BioStem Technologies Announces Filing of Restated Financial Statements • GlobeNewswire Inc. • 11/13/2025 09:01:00 PM
- BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes • GlobeNewswire Inc. • 11/05/2025 09:05:00 PM
- BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters • GlobeNewswire Inc. • 11/05/2025 12:00:00 PM
- BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers • GlobeNewswire Inc. • 10/31/2025 11:00:00 AM
- BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025 • GlobeNewswire Inc. • 10/30/2025 08:05:00 PM
